PT Kalbe Farma Tbk. Statistics
Total Valuation
PT Kalbe Farma Tbk. has a market cap or net worth of 3.99 billion. The enterprise value is 3.88 billion.
| Market Cap | 3.99B |
| Enterprise Value | 3.88B |
Important Dates
The next estimated earnings date is Friday, February 14, 2025.
| Earnings Date | Feb 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -0.86% |
| Shares Change (QoQ) | -0.48% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 18.85B |
Valuation Ratios
The trailing PE ratio is 19.61.
| PE Ratio | 19.61 |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 3.02 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.25, with an EV/FCF ratio of 14.69.
| EV / Earnings | 19.05 |
| EV / Sales | 1.95 |
| EV / EBITDA | 13.25 |
| EV / EBIT | 15.65 |
| EV / FCF | 14.69 |
Financial Position
The company has a current ratio of 4.15, with a Debt / Equity ratio of 0.03.
| Current Ratio | 4.15 |
| Quick Ratio | 2.32 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.16 |
| Debt / FCF | 0.19 |
| Interest Coverage | 70.91 |
Financial Efficiency
Return on equity (ROE) is 13.40% and return on invested capital (ROIC) is 10.36%.
| Return on Equity (ROE) | 13.40% |
| Return on Assets (ROA) | 8.92% |
| Return on Capital (ROIC) | 10.36% |
| Revenue Per Employee | 164,189 |
| Profits Per Employee | 15,742 |
| Employee Count | 13,108 |
| Asset Turnover | 1.15 |
| Inventory Turnover | 2.84 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -17.16% in the last 52 weeks. The beta is 0.21, so PT Kalbe Farma Tbk.'s price volatility has been lower than the market average.
| Beta (5Y) | 0.21 |
| 52-Week Price Change | -17.16% |
| 50-Day Moving Average | 0.13 |
| 200-Day Moving Average | 0.11 |
| Relative Strength Index (RSI) | 43.07 |
| Average Volume (20 Days) | 3,495 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, PT Kalbe Farma Tbk. had revenue of 2.12 billion and earned 203.45 million in profits. Earnings per share was 0.00.
| Revenue | 2.12B |
| Gross Profit | 806.71M |
| Operating Income | 263.50M |
| Pretax Income | 269.80M |
| Net Income | 203.45M |
| EBITDA | 308.61M |
| EBIT | 263.50M |
| Earnings Per Share (EPS) | 0.00 |
Balance Sheet
The company has 285.10 million in cash and 49.10 million in debt, giving a net cash position of 235.99 million.
| Cash & Cash Equivalents | 285.10M |
| Total Debt | 49.10M |
| Net Cash | 235.99M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 1.58B |
| Book Value Per Share | 0.03 |
| Working Capital | 853.89M |
Cash Flow
In the last 12 months, operating cash flow was 327.35 million and capital expenditures -63.55 million, giving a free cash flow of 263.79 million.
| Operating Cash Flow | 327.35M |
| Capital Expenditures | -63.55M |
| Free Cash Flow | 263.79M |
| FCF Per Share | n/a |
Margins
Gross margin is 38.02%, with operating and profit margins of 12.42% and 9.59%.
| Gross Margin | 38.02% |
| Operating Margin | 12.42% |
| Pretax Margin | 12.71% |
| Profit Margin | 9.59% |
| EBITDA Margin | 14.54% |
| EBIT Margin | 12.42% |
| FCF Margin | 12.43% |
Dividends & Yields
PT Kalbe Farma Tbk. does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 46.55% |
| Buyback Yield | 0.86% |
| Shareholder Yield | 0.86% |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
PT Kalbe Farma Tbk. has an Altman Z-Score of 12.31.
| Altman Z-Score | 12.31 |
| Piotroski F-Score | n/a |